Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0231

Advisory board · Dr. Gabriel Vogel

17 Jan 2026 · Virtual · Dr. Gabriel Vogel, Uniklinik Köln · MSL Rachel Adeyemi · Aurelin

ReviewedVeeva CRMENG-0231—

Capture insight from this engagement

Location: Uniklinik Köln
Therapeutic area: Immunology
Country: Germany
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Aurelin (aurelinate)

Topics discussed

Phase IIb efficacy
Adolescent population
JAK1/TYK2 selectivity

Scientific content used

JAK selectivity review

Questions raised

How does selectivity compare with approved JAK inhibitors?

Notes

Advisory board with allergist at Uniklinik Köln. Discussed phase iib efficacy, adolescent population, jak1/tyk2 selectivity.

Insights captured (1)

Capture insight

INS-0078Medium
Phase IIb efficacy
Phase IIb efficacy: request for data reported by allergist (DE).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 4
Depth of exchange: 5
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0231

Audit history (0)

All create, update and approval events for this record

No audit events in sample data